MYCN and cancer: detected copy number alterations in 4,577 human cancer samples representing nine different solid cancers and discovered that cell-derived enhancers were co-amplified with oncogenes in multiple solid tumors, including MYCN, which bore a compact relationship with drug resistance in medulloblastoma (55).